JO3006B1 - املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك - Google Patents

املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك

Info

Publication number
JO3006B1
JO3006B1 JOP/2006/0300A JOP20060300A JO3006B1 JO 3006 B1 JO3006 B1 JO 3006B1 JO P20060300 A JOP20060300 A JO P20060300A JO 3006 B1 JO3006 B1 JO 3006B1
Authority
JO
Jordan
Prior art keywords
phenoxy
thio
acetic acid
acid derivatives
lysine salts
Prior art date
Application number
JOP/2006/0300A
Other languages
Arabic (ar)
English (en)
Inventor
F Abdel-Magid Ahmed
Roessler Armin
Mehrman Steven
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of JO3006B1 publication Critical patent/JO3006B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/56—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C321/00—Thiols, sulfides, hydropolysulfides or polysulfides
    • C07C321/24—Thiols, sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C07C321/28—Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C07C59/70—Ethers of hydroxy-acetic acid, e.g. substitutes on the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JOP/2006/0300A 2005-09-14 2006-09-07 املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك JO3006B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71713705P 2005-09-14 2005-09-14

Publications (1)

Publication Number Publication Date
JO3006B1 true JO3006B1 (ar) 2016-09-05

Family

ID=37865545

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2006/0300A JO3006B1 (ar) 2005-09-14 2006-09-07 املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك

Country Status (30)

Country Link
US (2) US7709682B2 (enExample)
EP (1) EP1937065B1 (enExample)
JP (1) JP5467770B2 (enExample)
KR (5) KR20180079468A (enExample)
CN (1) CN101304656B (enExample)
AR (1) AR058044A1 (enExample)
AU (1) AU2006291006B2 (enExample)
BE (1) BE2025C533I2 (enExample)
BR (1) BRPI0615835B8 (enExample)
CA (1) CA2622722C (enExample)
CY (1) CY2025023I2 (enExample)
DK (1) DK1937065T3 (enExample)
ES (1) ES2535427T3 (enExample)
FI (1) FIC20253005I1 (enExample)
FR (1) FR25C1030I2 (enExample)
GT (1) GT200600420A (enExample)
HN (1) HN2006032171A (enExample)
HU (2) HUE025185T2 (enExample)
JO (1) JO3006B1 (enExample)
LT (1) LTC1937065I2 (enExample)
LU (1) LUC50018I2 (enExample)
NL (1) NL301339I2 (enExample)
NZ (1) NZ566504A (enExample)
PE (1) PE20070434A1 (enExample)
PL (1) PL1937065T3 (enExample)
PT (1) PT1937065E (enExample)
SI (1) SI1937065T1 (enExample)
TW (1) TWI414510B (enExample)
UY (1) UY29791A1 (enExample)
WO (1) WO2007033231A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539403C (en) * 2003-09-19 2013-11-19 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
UA87467C2 (xx) * 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
PE20080188A1 (es) * 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
JP5694941B2 (ja) 2008-10-17 2015-04-01 シーマベイ セラピューティクス,インコーポレイティド 小型高密度ldl粒子を減少させる方法
KR101813728B1 (ko) 2009-07-31 2017-12-29 그뤼넨탈 게엠베하 결정화 방법 및 생체이용률
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
EP2531200B1 (en) * 2010-02-06 2017-07-12 Grünenthal GmbH Crystallization method and bioavailability
CN103298469A (zh) 2010-08-31 2013-09-11 首尔大学校产学协力财团 PPARδ激动剂的胎儿重编程的用途
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
US20160279085A1 (en) * 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
ES2701094T3 (es) 2014-03-20 2019-02-20 Cymabay Therapeutics Inc Tratamiento de enfermedades colestáticas intrahepáticas
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
CA2944139C (en) 2014-04-11 2020-11-03 Cymabay Therapeutics, Inc. Treatment of nafld and nash
CN106470675A (zh) * 2014-06-26 2017-03-01 西玛贝医药公司 严重高甘油三酯血症的治疗
US20190276405A1 (en) * 2016-05-16 2019-09-12 Pulmagen Therapeutics (Asthma) Limited Crystal of quinoline derivative
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
JP2020533339A (ja) 2017-09-13 2020-11-19 ノバルティス アーゲー Fxrアゴニストを含む組合せ
JP7023371B2 (ja) 2017-09-26 2022-02-21 サイマベイ・セラピューティクス・インコーポレイテッド 胆汁うっ滞性そう痒の処置
MX2021005724A (es) 2018-11-16 2021-07-21 Cymabay Therapeutics Inc Tratamiento combinado contra nafld y nash.
WO2020102351A1 (en) 2018-11-16 2020-05-22 Cymabay Therapeutics, Inc. Treatment of obesity and its complications
EP4034236A1 (en) 2019-09-26 2022-08-03 Abionyx Pharma SA Compounds useful for treating liver diseases
US20210145774A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
WO2021097034A1 (en) 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Seladelpar for use in the treatment of intestinal barrier dysfunction and associated diseases
CN119735532A (zh) * 2019-11-21 2025-04-01 杭州百诚医药科技股份有限公司 α-氟代查耳酮类衍生物及其应用
RS65546B1 (sr) 2021-02-01 2024-06-28 Cymabay Therapeutics Inc Tretman holangiopatija sa seladelparom
WO2022189856A1 (en) 2021-03-08 2022-09-15 Abionyx Pharma Sa Compounds useful for treating liver diseases
KR20250139304A (ko) 2023-01-29 2025-09-23 사이머베이 쎄라퓨틱스, 인코퍼레이티드 만성 소양증 피부병의 치료
US20240252499A1 (en) 2023-01-29 2024-08-01 Cymabay Therapeutics, Inc. Treatment of uremic pruritus
WO2024175026A1 (zh) * 2023-02-24 2024-08-29 哈尔滨三联药业股份有限公司 含氮杂环类化合物及其医药用途
WO2025072489A2 (en) 2023-09-27 2025-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Analogues of n-lactoyl-phenylalanine, methods of synthesis, and methods of use
WO2026030533A1 (en) 2024-07-31 2026-02-05 Cymabay Therapeutics, Inc. Seladelpar for use in treating liver disease
US20260055055A1 (en) * 2024-07-31 2026-02-26 Cymabay Therapeutics, Inc. Process for making seladelpar
US20260207538A1 (en) 2024-12-20 2026-07-23 Gilead Sciences, Inc. Combinations for liver disease

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460689C3 (de) * 1974-12-20 1980-06-26 Klinge Pharma Gmbh & Co, 8000 Muenchen 13-disubstituierte Propanol-(2)-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US4125732A (en) * 1977-05-06 1978-11-14 American Cyanamid Company 2-Aryloxy-2-(phenoxyalkoxy)phenyl acetic acid and esters
DE3026924A1 (de) 1980-07-16 1982-02-18 Klinge Pharma GmbH & Co, 8000 München 1,3-diphenoxypropan-2-ol-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3028776A1 (de) 1980-07-29 1982-02-25 Klinge Pharma GmbH & Co, 8000 München Neue 1,3-diphenoxypropan-2-on-derivate sowie verfahren zu ihrer herstellung und diese enthaltende arzneimittel
EP0056172B1 (en) 1981-01-09 1985-04-03 FISONS plc Phenoxy- and thiophenoxy compounds, methods for their preparation and pharmaceutical formulations containing them
JPS58177934A (ja) 1982-04-13 1983-10-18 Takeda Chem Ind Ltd ベンゾキノン誘導体
ATE22072T1 (de) 1982-09-30 1986-09-15 Merck Frosst Canada Inc Leukotrienantagonisten, deren herstellung und diese enthaltende zusammensetzungen.
US4820867A (en) * 1983-04-21 1989-04-11 Merck Frosst Canada, Inc. Phenoxypropoxy halophenylacetic acids as leukotriene antagonists
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
JPS61268651A (ja) 1985-05-23 1986-11-28 Takeda Chem Ind Ltd フエニル酢酸誘導体およびその製造法
EP0204349A3 (de) * 1985-06-01 1990-01-03 Dr. Karl Thomae GmbH Neue heteroaromatische Aminderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH0714910B2 (ja) * 1988-12-13 1995-02-22 塩野義製薬株式会社 安定な結晶性の塩およびそれを含有するトロンボキサン受容体拮抗剤
US5487008A (en) * 1990-04-20 1996-01-23 The Regents Of The University Of Michigan Method and system for detecting the misfire of a reciprocating internal combustion engine in frequency domain
CA2092152A1 (en) * 1992-03-23 1993-09-24 Azuma Igarashi Phenoxyacetic acid compounds and medical preparations containing them
US5726165A (en) * 1994-07-29 1998-03-10 Smithkline Beecham P.L.C. Derivatives of 4-(2-aminoethyl)phenoxymethyl-phosphonic and -phosphinic acid and pharmaceutical and veterinary uses therefor
JP2002503202A (ja) 1996-02-02 2002-01-29 メルク エンド カンパニー インコーポレーテッド 抗糖尿病薬
CA2244831A1 (en) 1996-02-02 1997-08-07 John T. Olson Method of treating diabetes and related disease states
JP3268242B2 (ja) 1996-11-14 2002-03-25 三共株式会社 縮合複素環化合物を含有する医薬
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
CN1543451A (zh) * 2001-06-07 2004-11-03 过氧化物酶体增生剂激活的受体的调节剂
EP1414778A1 (en) 2001-07-30 2004-05-06 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their use as antidiabetics etc.
WO2003016291A1 (en) 2001-08-10 2003-02-27 Nippon Chemiphar Co., Ltd. ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ
MXPA04003398A (es) 2001-10-12 2004-11-22 Nippon Chemiphar Co Activador para el receptor o activado con el proliferador de peroxisoma.
ITRM20020014A1 (it) 2002-01-15 2003-07-15 Sigma Tau Ind Farmaceuti Derivati di acidi a-feniltiocarbossilici e a-fenilossicarbossilici utili per il trattamento di patologie che rispondono all'attivazione del
JP4383177B2 (ja) 2002-03-01 2009-12-16 スミスクライン ビーチャム コーポレーション hPPAR活性化剤
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
CA2499380A1 (en) * 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
KR20050061562A (ko) * 2002-10-28 2005-06-22 노보 노르디스크 에이/에스 신규 화합물, 그들의 제제 및 사용
DE60332860D1 (de) * 2002-10-28 2010-07-15 High Point Pharmaceuticals Llc Neue verbindungen, die sich f r die behandlung von durch ppar vermittelten krankheiten eignen
PL378110A1 (pl) 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek
JP2007502815A (ja) * 2003-08-20 2007-02-15 イーライ リリー アンド カンパニー Ppar調節因子
UA87467C2 (xx) * 2003-09-19 2009-07-27 Янссен Фармацевтика Н.В 4-((феноксіалкіл)тіо)феноксіоцтова кислота та її аналоги$4-((феноксиалкил)тио)феноксиуксусная кислота и ее аналоги
CA2539403C (en) * 2003-09-19 2013-11-19 Janssen Pharmaceutica N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
ATE362367T1 (de) 2003-10-31 2007-06-15 Janssen Pharmaceutica Nv Phenoxyessigsäure-derivate als peroxisom- proliferator-aktivierte rezeptor (ppar) dual- agonisten
ATE461932T1 (de) 2004-04-21 2010-04-15 Schering Corp Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
CN1997619B (zh) * 2004-07-01 2010-08-25 霍夫曼-拉罗奇有限公司 包含乙炔基的苯基衍生物
MY145712A (en) 2004-09-15 2012-03-30 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
MY147518A (en) * 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
JO3006B1 (ar) * 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0618963D0 (en) * 2006-09-26 2006-11-08 Ucl Business Plc Formulations and composites with reactive fillers

Also Published As

Publication number Publication date
KR20180079468A (ko) 2018-07-10
CY2025023I1 (el) 2026-02-25
AR058044A1 (es) 2008-01-23
NL301339I2 (nl) 2025-09-16
WO2007033231A3 (en) 2007-10-11
CN101304656A (zh) 2008-11-12
KR20160079129A (ko) 2016-07-05
LTC1937065I2 (enExample) 2025-12-29
LUC50018I2 (enExample) 2026-05-05
ES2535427T3 (es) 2015-05-11
JP5467770B2 (ja) 2014-04-09
AU2006291006B2 (en) 2012-09-13
HN2006032171A (es) 2011-03-15
US7709682B2 (en) 2010-05-04
HUS2500034I1 (hu) 2025-09-28
TWI414510B (zh) 2013-11-11
WO2007033231A2 (en) 2007-03-22
EP1937065A4 (en) 2010-07-21
LUC50018I1 (enExample) 2025-07-29
CN101304656B (zh) 2013-03-13
SI1937065T1 (sl) 2015-05-29
KR20130100800A (ko) 2013-09-11
US8669288B2 (en) 2014-03-11
EP1937065A2 (en) 2008-07-02
TW200804256A (en) 2008-01-16
FIC20253005I1 (fi) 2025-07-31
HK1122699A1 (en) 2009-05-29
CY2025023I2 (el) 2026-02-25
NZ566504A (en) 2010-11-26
PL1937065T3 (pl) 2015-07-31
FR25C1030I1 (fr) 2025-09-26
KR20150013952A (ko) 2015-02-05
PT1937065E (pt) 2015-03-04
GT200600420A (es) 2007-05-08
PE20070434A1 (es) 2007-05-14
HUE025185T2 (en) 2016-02-29
UY29791A1 (es) 2006-12-29
CA2622722A1 (en) 2007-03-22
DK1937065T3 (en) 2015-02-09
EP1937065B1 (en) 2015-01-28
BRPI0615835A2 (pt) 2011-05-31
US20110105616A1 (en) 2011-05-05
FR25C1030I2 (fr) 2026-02-06
BRPI0615835B8 (pt) 2021-05-25
BE2025C533I2 (enExample) 2026-02-02
BRPI0615835B1 (pt) 2020-04-22
AU2006291006A1 (en) 2007-03-22
CA2622722C (en) 2016-04-19
KR20080046695A (ko) 2008-05-27
US20070060649A1 (en) 2007-03-15
JP2009514797A (ja) 2009-04-09
LTPA2025530I1 (enExample) 2025-08-25

Similar Documents

Publication Publication Date Title
CY2025023I2 (el) Νεα αλατα λυσινης παραγωγων 4- ((φαινοξυαλκυλ)θειο)-φαινοξυοξεικου οξεος
EA200870103A1 (ru) Феноксиуксусные кислоты в качестве активаторов ppar дельта
DE60330757D1 (de) Verwendung von pyridylamiden als angiogenesehemmer
EA201070699A1 (ru) Композиции 3-(6-(1-2,2-дифторбензо[d][1,3]диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
EA201690035A1 (ru) Новые циклические производные азабензимидазола, используемые в качестве антидиабетических агентов
EA201070698A1 (ru) Твердые формы 3-(6-(1-(2,2-дифторбензо[d][1,3]-диоксол-5-ил)циклопропанкарбоксамидо)-3-метилпиридин-2-ил)бензойной кислоты
CY1109299T1 (el) Μεθανοσουλφονικο αλας 3-[(2-{[4-εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1-μεθυλο-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλο-αμινο]-προπιονικου αιθυλεστερα και η χρηση αυτου ως φαρμακευτικο μεσο
NO20085121L (no) Benzimidazolderivater, deres fremstillingsmate, deres anvendelse som FXR-agonister og farmasoytiske blandinger inneholdende samme
DE502006002886D1 (de) Dipyridyl-dihydropyrazolone und ihre verwendung 4- (pyridin-3-yl) -2- (pyridin-2-yl) -1,2-dihydro-3h-pyrazol-3-on derivate als spezifische hemmstoffe der hif-prolyl-4-hydroxylasen zur behandlung kardiovaskulärer und hämatologischer erkrankungen
UA92025C2 (en) Indole compounds
EP2578574A4 (en) OPTICALLY ACTIVE DIBENZYLAMINE DERIVATIVE AND METHOD OF MANUFACTURING THEREOF
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
UA97817C2 (ru) Гетероциклические производные 4-(метилсульфонил)фенила и их применение
DK2358717T3 (da) Aminotetrahydropyraner som dipeptidylpeptidase-iv-inhibitorer tilbehandling eller forebyggelse af diabetes
EA201390934A1 (ru) Композиции и способы модулирования fxr
EA200702198A1 (ru) Фармацевтические составы
TW200716107A (en) Polymorphs of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazole-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
EA200901514A1 (ru) Новая сольватная и кристаллическая форма производных карбамоилциклогексана
ATE524450T1 (de) 5-phenyl-isoxazol-3-carboxamid-derivate als trpv1-modulatoren
EA200801691A1 (ru) Соль янтарной кислоты 1-[2-(2-хлор-4-{[(r)-2-гидрокси-2-(8-гидрокси-2-оксо-1,2-дигирдохинолин-5-ил)этиламино]метил}-5-метоксифенилкарбамоил)этил]пиперидин-4-илового эфира бифенил-2-илкарбаминовой кислоты и ее применение для лечения легочных расстройств
ATE529404T1 (de) Phenoxyessigsäuren als ppar-delta-aktivatoren
NZ751217A (en) Benzo-fused heterocyclic derivatives useful as agonists of gpr120
MY210500A (en) Potassium salt of 2-[(4s)-8-f1uoro-2-4-(-3-methoxyphenyl)piperazin-1 -yl]-3-[2- methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl] acetic acid
EA200700648A1 (ru) 4-((феноксиалкил)тио)феноксиуксусные кислоты и аналоги
GB0407025D0 (en) Novel compounds